Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab and Tuvonralimab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Not Yet RecruitingNCT07502027
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Huazhong University of Science and Technology 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07129018
What this trial is testing

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer (BTC)First-line Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07673835
What this trial is testing

Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II）

Who this might be right for
Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07116577
What this trial is testing

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Who this might be right for
mCRC
Jinan Central Hospital 37
Testing effectiveness (Phase 2)Looking for participantsNCT07315854
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer (GC)Gastroesophageal Junction CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07053332
What this trial is testing

A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma

Who this might be right for
Esophagogastric Junction/Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07379398
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 28
Testing effectiveness (Phase 2)Looking for participantsNCT07070700
What this trial is testing

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)
Fudan University 56
Testing effectiveness (Phase 2)Looking for participantsNCT07530445
What this trial is testing

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Who this might be right for
Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07490002
What this trial is testing

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

Who this might be right for
Esophageal Squamous Carcinoma
Changhai Hospital 33
Not applicableNot Yet RecruitingNCT07115550
What this trial is testing

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
Huai'an First People's Hospital 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07828873
What this trial is testing

A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma

Who this might be right for
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Zhengzhou University 34
Testing effectiveness (Phase 2)Looking for participantsNCT06878222
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Who this might be right for
Cervical Cancers
Obstetrics & Gynecology Hospital of Fudan University 35
Testing effectiveness (Phase 2)Looking for participantsNCT06951997
What this trial is testing

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital 33
Testing effectiveness (Phase 2)Looking for participantsNCT07389629
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Who this might be right for
Iparomlimab and TuvonralimabClear Cell Renal Cell CarcinomaNeoadjuvant Therapy
Sun Yat-sen University 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07041788
What this trial is testing

Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

Who this might be right for
Cancer
Second Affiliated Hospital of Nanchang University 25
Large-scale testing (Phase 3)Looking for participantsNCT06749899
What this trial is testing

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Who this might be right for
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center 580
Testing effectiveness (Phase 2)Active Not RecruitingNCT07776639
What this trial is testing

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

Who this might be right for
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Yongxu Jia 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07407452
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancers
Jiangsu Cancer Institute & Hospital 50
Next Page